Bioxytran, Inc.
BIXT
$0.1567
-$0.0054-3.33%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.12M | 2.13M | 2.50M | 2.80M | 2.65M |
| Depreciation & Amortization | 7.90K | 8.80K | 9.10K | 9.80K | 8.30K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.24M | 2.76M | 3.40M | 3.85M | 3.81M |
| Operating Income | -2.24M | -2.76M | -3.40M | -3.85M | -3.81M |
| Income Before Tax | -2.38M | -2.92M | -3.68M | -4.47M | -4.47M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.38 | -2.92 | -3.68 | -4.47 | -4.47 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 26.60K | 35.10K | 69.90K | 70.70K | 90.30K |
| Net Income | -2.36M | -2.88M | -3.61M | -4.40M | -4.38M |
| EBIT | -2.24M | -2.76M | -3.40M | -3.85M | -3.81M |
| EBITDA | -2.23M | -2.75M | -3.39M | -3.84M | -3.80M |
| EPS Basic | -0.02 | -0.02 | -0.02 | -0.03 | -0.03 |
| Normalized Basic EPS | -0.01 | -0.01 | -0.01 | -0.02 | -0.02 |
| EPS Diluted | -0.02 | -0.02 | -0.02 | -0.03 | -0.03 |
| Normalized Diluted EPS | -0.01 | -0.01 | -0.01 | -0.02 | -0.02 |
| Average Basic Shares Outstanding | 558.74M | 613.37M | 623.43M | 575.63M | 536.31M |
| Average Diluted Shares Outstanding | 558.74M | 613.37M | 623.43M | 575.63M | 536.31M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |